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DObjective: We sought to examine the hemodynamic effects at 1 month and 1 year of left ventricular reconstruction by
means of endoventricular patch plasty for patients with acute or chronic, very severe post–myocardial infarction heart failure
who would have been systematically excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial.
Methods: From 2002 to May 2008, 274 patients underwent left ventricular reconstruction for post–myocardial infarction
scarring; 117 of these patients would not have been eligible for the STICH trial. The pertinent criteria for exclusion included
12 patients with no coronary vessel suitable for coronary artery bypass grafting; 17 patients within a month of myocardial
infarction, including 11with acute heart failure (8 septal ruptures and 3 cases of ventricular tachycardia); 48 patients receiving
intravenous inotropes, intra-aortic balloon pumping, or both; 15 patients with bifocal or posterior scarring; 4 patients sched-
uled for heart transplantation; and 21 patients meeting 5 other exclusion criteria. These patients (mean age, 64 years; age
range, 34–83 years) preoperatively had a mean 49% (range, 35%–75%) scarred left ventricular circumference, as deter-
mined by means of magnetic resonance imaging assessment. In the patients with chronic heart failure, the preoperative ejec-
tion fraction was 26%  4% (range, 9%–34%), the end-diastolic volume index was 130  43 mL/m2 (range, 62–343 mL/
m2), and the end-systolic volume index was 95 37 mL/m2 (range, 45–289 mL/m2). Mitral regurgitation was mild to severe
in 56 patients and associated with annular dilatation (35 mm) in 51 patients. A strategy of left ventricular reconstruction by
means of endoventricular circular suturing and patching excluded the scarred left ventricular wall and was balloon sized to
provide a diastolic volume of 50mL/m2. Circular patches were used for anteroseptoapical lesions, and triangular patches were
used for posterior lesions. The mitral valve was repaired in 51 patients, and coronary revascularization was performed in 105
patients (arterial grafts in 95 and mixed in 12). Seventy-eight patients had endocardectomy, and cryotherapy was used in 39
patients for ventricular tachycardia.
Results: Four in-hospital and 2 delayeddeaths occurred during thefirst year. In 101 patientswith chronic heart failure,magnetic
resonance imaging revealed that ejection fraction improved from 26%  4% preoperatively to 40%  8% at 1 month and
44%  11% at 1 year postoperatively. At these same time points, the end-diastolic volume index was reduced from 130 
43 mL/m2 to 81  27 and 82  25 mL/m2, respectively, and the end-systolic volume index was reduced from 96  45 mL/m2
to 50  21 and 47  20 mL/m2, respectively.
Conclusions: With minimal associated mortality, left ventricular reconstruction produces durable improvement in left
ventricular function in patients with a large scarred ventricular wall. Considering that this patient cohort would have been
systematically excluded from the STICH trial, care should be taken not to extrapolate that study’s results too widely so as
to inappropriately deny selected patients an effective treatment for ischemic cardiomyopathies with an injured ventricle.
(J Thorac Cardiovasc Surg 2011;141:905-16)Supplemental material is available online.
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The aim of this study is to show by means of hemodynamic
data and left ventricular (LV) wall-motion analyses 1 month
and 1 year after surgical intervention that in patients with is-
chemic cardiomyopathies (ICMs) with a widely scarred LV
wall and distended viable myocardium caused by eccentric
systolic motion, the exclusion of the scar by means of endo-
ventricular patch plasty (EVPP) is followed by a stable regres-
sion of LV remodeling and restoration of normal concentric
contraction of the LV wall surrounding the scarred area. The
pathophysiologies leading to ICM are diverse and complex,
including depressed but viable ischemic myocardium,
stunned or hibernatingmuscle, and asynergic fibrous scarring.rdiovascular Surgery c Volume 141, Number 4 905
Abbreviations and Acronyms
AHF ¼ advanced heart failure
CABG ¼ coronary artery bypass grafting
caDVI ¼ contractile area diastolic volume index
CMR ¼ cardiac magnetic resonance
EDVI ¼ end-diastolic volume index
EF ¼ ejection fraction
ESVI ¼ end-systolic volume index
EVPP ¼ endoventricular patch plasty
GLE ¼ gadolinium late enhancement
HF ¼ heart failure
ICM ¼ ischemic cardiomyopathy
IFV ¼ ischemic failing ventricle
LAD ¼ left anterior descending coronary artery
LAVI ¼ left atrial volume index
LV ¼ left ventricular
LVR ¼ left ventricular reconstruction
MI ¼ myocardial infarction
MR ¼ mitral regurgitation
MRI ¼ magnetic resonance imaging
NYHA ¼ New York Heart Association
SI ¼ sphericity index
STICH ¼ Surgical Treatments for Ischemic
Heart Failure
SVR ¼ surgical ventricular reconstruction
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DAlthough coronary artery bypass grafting (CABG) or percuta-
neous transluminal coronary intervention can treat ischemia,
only left ventricular reconstruction (LVR) is specifically de-
signed to address the scarring of themyocardial wall that trig-
gers remote negative LV remodeling.
First demonstrated in 1967 by Klein and associates1 and
confirmed byMcKay and coworkers,2 irreversible heart fail-
ure (HF) occurs when post–myocardial infarction (MI) scar
involves 20% of the LVarea or 40% of its perimeter. Since
1967, knowledge of post-MI HF has been expanded by nu-
merous studies showing that even after recanalization of the
culprit artery at the acute phase of MI, the LV wall almost
always becomes permanently scarred. In 80% to 100% of
such cases,3 the scarred wall shows extension from 6% to
80%. Twenty-seven percent of patients with restoration of
Thrombolysis in Myocardial Infarction grade 3 flow after
MI4 have LV dilatation with HF, a finding that correlates
with the conclusion of Gaudron and coworkers5 that at 18
months after MI, 20% of patients are in congestive HF.
Since 2002, our institutional assessment of the scarred left
ventricle after MI (with or without successful coronary re-
canalization) has been conducted in 840 patients by means
of magnetic resonance imaging (MRI). The extent of
gadolinium late enhancement (GLE) in 4 planes (2- and
4-chamber views, LVoutflow tract, and short axis at the level906 The Journal of Thoracic and Cardiovascular Surgof the papillary muscle base) allowed us to build a GLEmap
with the percentage of scarred LV perimeter (Figure 1) that
correlates to the classical centerline method.6 Ninety per-
cent of patients have 10% or greater scarred LV perimeter
(Figure 2), and 22% of these patients are in advanced HF
(AHF), according to the criteria of the European Society
of Cardiology,7 or in acute HF. AHF exceeds 53% for those
patients with a scarred LV perimeter of greater than 50%.
The degree of AHF and the percentage of scarred circumfer-
ence are more increased in those patients (n¼ 229) who had
recanalization of an occluded coronary artery during the
acute phase of MI (Figure E1, A and B). Recanalization,
per se, does not carry deleterious effects (unless performed
too late in a totally necrotic territory initiating the ‘‘myocar-
dial reperfusion induced injury’’8) but emergency recanali-
zation was applied to the sickest patients.
These highly scarred left ventricles in patients with
chronic HF and New York Heart Association (NYHA) class
III or IV, in those with AHF, or in those with acute HF are
often beyond any response to medical treatment, to resynch-
ronization, or to revascularization therapies.9 They repre-
sent ischemic failing ventricles (IFVs), the most severe
category of ICM.MATERIALS AND METHODS
From 2002 to May 2008, 274 patients after MI underwent LVR with
EVPP at our institution .10 One hundred seventeen patients had LV scarring
of greater than 35%, (chronic NYHA class III/IVor acute HF) and met the
exclusion criteria for the Surgical Treatments for Ischemic Heart Failure
(STICH) trial, as listed in the ‘‘STICH investigator’s handbook.’’ The per-
tinent exclusion criteria are listed in Table 1.
All 117 patients had left and right heart catheterization, coronary angi-
ography, and programmed ventricular stimulation to detect a potential ven-
tricular arrhythmia induced by the scar. Asynergic scarring (dyskinetic or
akinetic), systolic function (ejection fraction [EF], end-diastolic volume
index [EDVI], and end-systolic volume index [ESVI]) and diastolic
function (left atrial volume index [LAVI])11 were assessed by means of
MRI to be more reliable.12 A GLE map was established for all patients
with a 1.5-T imager (Siemens Sonata). For patients with intra-aortic bal-
loon pumping or previous pacemaker or defibrillator implantation contra-
indicating MRI, the hemodynamic parameters were assessed by means
of echocardiographic analysis, angiographic analysis, and computed tomo-
graphic scanning.
Table 2 shows the clinical characteristics and hemodynamic data for the
106 patients with chronic AHF and 11 patients with acute HF. Mitral insuf-
ficiency (56 patients) was quantified by using proximal isovelocity surface
area, and the distribution of classification13 is also presented in Table 2.
The preoperative assessment confirmed the fact that the trigger of HF
was a large scarred akinetic wall (mean, 49.5% of LV perimeter; range,
35%–75%) and also that the mechanism that induces ventricular dilatation
is (functionally but not histologically speaking) a deleterious systolic ec-
centric (centrifugal) motion (Figure E2 and Videos 1-3) of the noninfarcted
myocardium surrounding the scar. This eccentric motion is best seen on
MRI, immediately after MI, when the wall is still necrotic (no reflow or mi-
crovascular obstruction). The ongoing dilatation process is correlated to the
amount of myocardial loss; it might take only a few weeks if this loss ex-
ceeds 50% of the left ventricle (evolving aneurysms) or up to months and
years. This ineffective contraction is explained by ‘‘the extent of shortening
of the remaining myocardium exceeding its physiological limits.’’1ery c April 2011
FIGURE 1. Gadolinium late enhancement (GLE)map of an 85-year-old patient with previous obstruction and stenting of the left anterior descending cor-
onary artery. The scar exceeded 50% of the left ventricular wall perimeter. LVOT, Left ventricular outflow tract; EDVI, end-diastolic volume index; ESVI,
end-systolic volume index; E. F., ejection fraction; LAVI, left atrial volume index; C.A.D.V.I., contractile area diastolic volume index.
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DGoals and Technique of LVR
LVR by means of EVPP was proposed in 198410 to rebuild from inside
the left ventricle after a large blind endocardectomy,14 before the implant-
able defibrillator era, to treat intractable ventricular arrhythmias after MI.
LVR is an etiological technique with the goals of exclusion of the scarred
left ventricle, prevention of progressive dilation, and creation of an appro-
priate diastolic chamber size.
The feasibility of the ventricular reconstruction is based on the assess-
ment of the theoretical contractile area diastolic volume index (caDVI;
Figure 1) obtained by the subtraction from the global EDVI of one hun-
dredth of the product EDVI multiplied by the mean percentage of scarred
wall perimeter, as measured by using the GLE map. If the caDVI is greater
than 45 to 50 mL/m2, an efficient contractile cavity can be rebuilt irrespec-
tive of borderline severe cases with pulmonary hypertension, mitral regur-
gitation (MR), and renal failure. The correlation between the caDVI and the
immediate postoperative EDVI is demonstrated in specific case examples
(Figures 4, 5, E4, and E5, and Videos 6-15).
The LVR technique (Figure 3) comprises 4 elements: eliminating mitral
insufficiency, achieving coronary revascularization, endocardectomy, and
ventricular cavity remodeling. The complete technique is conducted on
the arrested heart (crystalloid cardioplegia and continuous local cooling).
The majority of mitral repairs were accomplished by means of posterior
annuloplasty (with a 6/7-cm polytetrafluoroethylene strip) to treat dilatationThe Journal of Thoracic and Cagreater than 35 to 38mm in diameter. More rarely (<5%),MR can be related
to scarred papillary muscle or a displaced papillary muscle root. The situa-
tion then requires papillary muscle reimplantation or mitral replacement.
All suitable vessels for bypass on the noninfarcted area and also the in-
farcted vessel must be revascularized. With regard to the occluded left an-
terior descending coronary artery (LAD), we always try to bypass it, even if
the run-off is not seen on the angiogram (but is visible on a computed to-
mographic scan). It must also be mentioned that patent LADs stented after
recanalization are also bypassed as antiplatelet therapy is discontinued dur-
ing the postoperative phase.
Endocardectomy is accomplished in a blind fashionwith cryotherapy on
the edge of the resection in patients when spontaneous or inducible ventric-
ular tachycardia is detected during the preoperative assessments.15
The scarred LV wall is excluded by an endoventricular circumferential
suture (Fontan technique), which is placed at the border between the
scarred and normal myocardium. Placement can either be straightforward
by following the delineated endocardial fibrous scar (‘‘contractility trail’’;
Figure 3, B) or be guided by the GLE map when the endoventricular scar is
not well delineated when patients undergo surgical intervention during the
first weeks or months after MI.
LVR should maintain a normal diastolic volume to avoid an excessive
volume reduction with its immediate (low cardiac output) or delayed (re-
strictive cardiomyopathy) consequences. This is accomplished by tyingrdiovascular Surgery c Volume 141, Number 4 907
FIGURE 2. Linear relationship of infarct size/degree of advanced heart failure (AHF) I (840 gadolinium late enhancement maps after myocardial infarc-
tion). A, Scar extension (percentage of the left ventricular [LV] perimeter) in 840 patients afterMI. B, percentage of AHF according to the percentage of scar
extension.
TABLE 1. Categorization of patients by STICH trial exclusion
criteria*
Exclusion
No. of
patients
No suitable vessel for CABG 12
Combined anterior and posterior
or posterior and posterolateral
localization of the asynergic scar
15
Within 1 mo of MIy 17
Class IV patients or in cardiogenic shock
requiring permanent or recurrent
administration of intravenous inotropes
or intra-aortic balloon pumping
48
On heart transplantation waiting list 4
Right and circumflex stenosis not
amenable for CABG
5
PCI planned 6
Noncardiac illness imposing substantial
operative mortality
3
Miscellaneousz 7
STICH, Surgical Treatments for Ischemic Heart Failure; CABG, coronary artery by-
pass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention.
*‘‘STICH investigator’s handbook,’’ chapter 3, p. 17-18. yIncludes 11 cases of acute
heart failure caused by septal or free wall rupture in 8 patients and refractory ventric-
ular fibrillation in 3 patients. zIncludes more than 1 prior cardiac surgery and aortic
valve disease requiring replacement.
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theoretical physiological diastolic volume of the patient (ie, approximately
50 mL/m2). This diastolic volume balloon sizing, which has been used since
1998,16 has changed the long-term results of LVR, avoiding the recurrence
of remodeling noticed in our previous series17 and those of others.18
The closure of the rebuilt LV cavity is done with a patch tailored to the
appropriate shape and size of the remaining orifice. This patch (Dacron, au-
tologous pericardium, or, rarely, a piece of autologous fibrous endocardium
with a septal hinge) is anchored on the ‘‘clothesline’’ of the endoventricular
suture. Finally, the excluded fibrous areas are sutured above the patch, avoid-
ing blockage of the revascularized coronary vessel or simply folded on the
patch in case of very large exclusion of the septum to avoid plication of the
septum and distortion of the right ventricular cavity.
Concomitant Procedures (Table 3)
CABG was performed in 105 (89.7%) patients, with a mean number of
1.9 grafts. The LAD was grafted in 88 patients. Concomitant mitral valve
repair or replacement was performed in 51 patients. This included annulo-
plasty (n ¼ 31), annuloplasty plus the edge-to-edge (Alfieri) technique
(n¼ 18, totally discontinued since 2005), and valve replacement (1 for a lat-
eral aneurysm and 1 for an anterior valve rupture after prior Alfieri repair).
EVPP can be applied in all types of scarred ventricles, most often for the
anteroseptoapical region with an oval or circular patch but also for poste-
rior, posteroseptal, posteroapical, and posterolateral asynergieswith a trian-
gular patch, with the basis attached on or near the mitral annulus to stabilize
its geometry. The asynergy can be dyskinetic (transmural scar) or, more of-
ten, akinetic (subendocardial scar after coronary revascularization19). In
this late circumstance the epicardial layer of myocardium covering the
scar becomes progressively useless when the endocardial scar is rigidified
by fibrosis and calcification, as reported by Bax and colleagues.20
LVR is efficient because the asynergic patch (5 to 9 cm2) replaces an LV
asynergicareaofbetween60 to110cm2 (assessedby theendocardial resection).
The diameter of the patch represents less than 20% of the LV perimeter. With
thepatchanchoredon thecontractilemyocardium, thedeleteriouseccentric sys-
tolic (centrifugal)motion is replacedby aphysiological concentric systolic con-
traction (centrepital) (Figure E3 and Videos 4 and 5). This restoration of
a normal contraction was demonstrated in 199521 and 200422 by studies show-
ingnormalizationof thearchitectureofpressure-length loops in the remote area.
Figure 4 shows LVR for a large anteroseptoapical scar. Other locations
are also shown in the Electronic Appendix. Posterior scarring (Figure E4
and Videos 7-12) is treated with a triangular patch. The base is sutured
on the posterior mitral annulus, its external edge is set on the contractile lat-
eral wall, its internal edge is set on the contractile septum, and its apex is set908 The Journal of Thoracic and Cardiovascular Surgat the base of the papillary muscle. Thus the patch restores normal distance
between the posterolateral papillary muscle and the septum. Figure E5
(Videos 12-15) also shows an anterior septal rupture that is excluded
from the rebuilt LV cavity by a patch anchored above the necrotic anterior
and septal walls, as published first in 1987.23 In such cases sutures set at the
limit of necrotic tissues must be transmural and reinforced by Teflon felt.
Statistical Analysis
Data are expressed as medians  standard deviations. Repeated-
measures analysis of variance was performed to analyze the ventricular in-
dices. All analyses were performed with SPSS 17.0 software (SPS, Inc,
Chicago, Ill). Mean preoperative hemodynamic values were recalculated
in 101 patients (106 patients with chronic HF) surviving at 1 year.ery c April 2011
TABLE 2. Clinical and hemodynamic characteristics of 117 STICH
trial noncandidates undergoing LVR
Characteristic Value Range
Age (y) Mean ¼ 64 35–83
Age>70 y 49 (42%) patients
Male sex 90 (76.9%) patients
Prior PCI 58 (49.6%) patients
Mitral regurgitation
Mild (EROA<0.2 cm2) 17 (14.5%) patients
Moderate to severe
(EROA>0.2 cm2)
49 (41.9%) patients
Pulmonary pressure (mm Hg) Mean ¼ 37 17–83
Ventricular tachycardia present
or inducible*
39 (34.5%) patients
EF
In 106 patients with chronic
heart failure
26%  4% 9%–34%
In 11 patients with acute
heart failure
41%  6.7% 32%–50%
EDVI (mL/m2), n ¼ 106 130  43 62–343
ESVI (mL/m2), n ¼ 106 95  37 45–289
LAVI (mL/m2), n ¼ 55 51 19 17–94
GLE (% of scarred LV
perimeter)
49.5 35–77
STICH, Surgical Treatments for Ischemic Heart Failure; LVR, left ventricular recon-
struction; PCI, percutaneous coronary intervention; EF, ejection fraction; EDVI,
end-diastolic volume index; ESVI, end-systolic volume index; LAVI, left atrial vol-
ume index; GLE, gadolinium late enhancement; LV, left ventricular. *Evaluated in
113 patients.
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DRESULTS
Survival
Overall hospital mortality for all patients undergoing
EVPP (2002–2008) was 2.2% (6/274) and 1.3% (2/157)
in patients ‘‘suitable’’ based on the STICH criteria. In the
patient cohort meeting the STICH exclusionary criteria,
mortality was 3.4% (4/117). In this last series 8 surviving
patients were considered as not improved (‘‘disappointing
results’’) with persistent HF of NYHA class II/III, EF im-
provement of less than 5% to 7%, and a dilated left
ventricle (ESVI,>60mL/m2), with numerous hospital read-
missions and 2 late deaths during the first year.
At 1 year in the 51 patients undergoing mitral surgery,
there were 2 prostheses with normal function, no MR in
16 patients, mild MR in 28 patients, and moderate MR in
5 patients. The Kaplan–Meier survival curve (Figure 5)
shows a rate at 8 years of greater than 80% (complete
follow-up on 109/111 patients). Hospital readmission of
these patients for complete hemodynamic and electrophys-
iological assessment was systematically proposed 1 month,
1 year, and 3 years after surgical intervention.
Changes in Cardiac Function
Table 4 details the hemodynamic results after 1 month
and more than 1 year in the 111 survivors. The improvement
in LV systolic function is progressive from 1 month to 1The Journal of Thoracic and Cayear based on EF increase, from 26% before LVR up to
40% (statistically significant) and 44%, respectively, and
on ESVI, which decreased from 96 mL/m2 to 50 mL/m2
(statistically significant) and 47 mL/m2, respectively. The
improvement in diastolic function is characterized by the
decrease in LAVI (n ¼ 55 patients) from 51  19 to 39 
14 mL/m2 (P ¼ .001, paired test). In the group of patients
with acute HF, the encouraging result is obtained by the de-
crease in pulmonary hypertension from 62 to 38 mm Hg
(P ¼ .001, paired test) and the fact that almost normal
values in terms of ESVI (34 mL) and EDVI (67 mL) are
also obtained after 1 year (P ¼ .01).
Figures 4, 6, E3, and E4 (Videos 4-11) show the evolution
after 1 year of the progressive and durable regression of the
remodeling, in contrast with the 5 patients illustrating this ar-
ticle. This progressive and durable regression of the remod-
eling, in contrast to results seen in other publications,24,25 is
explained by the abolition of the deleterious eccentric
systolic motion with restoration of systolic concentric
contraction of the viable myocardium and the maintenance
of a physiological diastolic capacity by the diastolic
volume balloon sizing. The rebuilt contractile LV cavity in
the postoperative period can be spherical or elliptic: the
sphericity index (SI) analysis shows more often an increase
in SI at 1 month compared with the preoperative value but
a return to preoperative values at 1 year and to a normal SI
value (z0.30) at 3 years (Figures 4, 6, and E3, and Videos
4 and 5). This return to an elliptic shape is not imposed
by a shaper but linked to physiological contraction of the
LV cavity, irrespective of its immediate postoperative
morphology.
DISCUSSION
The results presented here for LVR in cases of severe IFV
speak for themselves. However, the recent report by Jones
and colleagues26 has raised serious questions with regard
to the effectiveness of this procedure and its value for all pa-
tients with ischemic HF. Because this report focuses on ex-
cluded STICH patients, it presents the opportunity to
provide contrast and delineate any undermining pitfalls in
the conduct and execution of the STICH trial.
In all types of HF (which is not an entity but a status in the
evolution of all cardiomyopathies), the first duty is to carry
out an efficient and reliable screening of the cause to under-
take, if possible, an etiological adapted therapy. In patients
with ICMs, the screening must determine whether the rea-
son why the heart is failing is linked with the myocardial is-
chemia or is a consequence of myocardial necrosis. STICH
criterion number 1 (ie, ‘‘coronary vessel suitable for CABG
and limited anterior wall asynergia’’ not precisely assessed)
addresses almost only the first cause of ischemic HF. This is
confirmed by the preoperative assessments of the 1,000 pa-
tients in arm 2 (57 in NYHA class IV) with analysis of the
Canadian Cardiovascular Society score but no assessmentrdiovascular Surgery c Volume 141, Number 4 909
FIGURE 3. Left ventricular reconstruction (L.V.R.) by means of endoven-
tricular circular patch plasty for postinfarction anteroseptoapical aneurysm.
A, Scarred wall affects more than 50% of the left ventricular circumfer-
ence. Contractile myocardium on the septum and lateral wall remote
from the scar is distended by eccentric motion. B, The endoventricular
purse-string suture (Fontan ‘‘trick’’) is set at the limit between the contrac-
tile and scarred wall, excluding all asynergic nonresectable areas. This
‘‘contractility trail’’ is easily seen when endocardial scar is fibrotic or cal-
cified (years after infarction) or guided by the gadolinium late enhancement
map in a recent infarct. C, An endoventricular suture that restores the nor-
mal curvature and concentric contraction of the contractile myocardium is
tied on a rubber balloon inflated at the normal diastolic volume (50mL/m2),
avoiding low cardiac output or delayed remodeling recurrence. D, Once
tied, the suture gives shape and size on the patch, which is anchored on
this ‘‘clothesline,’’ maintaining the myocardial circular reorganization.
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diastolic function, all markers of HF. It is also surprising
that in neither the ‘‘STICH investigator’s handbook’’ nor
in the published results26 is there any definition or descrip-
tion of the surgical technique of surgical ventricular recon-
struction (SVR). The only reference is the following:
‘‘certification of surgeon for performing SVR required evi-
dence of consistent [sic] post operative decrease in LV vol-
ume in 5 consecutive surviving patients.’’ There is no
mention of the value or percentage volume reduction that
a certified surgeon must be able to achieve. The 4-month
analysis (performed by using echocardiographic analysis
on only one third of the series) demonstrated an ESVI de-
crease of from 82 to 77 mL/m2 (6%) in the CABG group,
as opposed to 83 to 67 mL/m2 (19%) in the SVR group.
The complementary information about the STICH
trial presented by Michler at the American College of910 The Journal of Thoracic and Cardiovascular SurgCardiology in 2010 is based on 595 patients among the
1,000 patients of arm 2 (405 being excluded for death 86,
or lack of baseline studies!). In the group with a large left
ventricle (ESVI>90 mL/m2), for the 117 patients with
CABG plus SVR, 56% of them continue to have a dilated
left ventricle (ESVI>60 mL), and EF increased from 21%
to 27%; for the 118 patients with CABG alone, 76% con-
tinue to have a large left ventricle, and EF increased from
22% to 25%. These ESVI values of greater than the thresh-
old of 60 mL/m2 reflect poor prognosis,27 and these results
contrast with those of our series, in which early ESVI de-
creased from 96 to 50 mL/m2 (44%) and there was an in-
crease in EF from 26% to 44% at 1 year. Thus these very
limited improvements in ESVI and EF in the STICH trial
might be misleading because SVR in this trial shows similar
results to those of classical resection of an apical aneurysm
followed by linear suturing, overlapping, or plicature, as de-
scribed by Cooley and associates in 195828 and by Stoney
and coworkers29 and criticized by Froehlich and Falsetti30
(analyzing 6 postoperative angiograms after 18 anterior
wall resections) as inefficient on LV performance.
Our precise methodology for viability and scar evalua-
tion provides a benchmark for LVR preoperative evaluation
and feasibility and contrasts starkly with what was attemp-
ted by the STICH trial, whereas the original protocol re-
quired greater than 35% asynergia from the anterior wall
and an ESVI of greater than 60 mL/m2; subsequent changes
to the protocol dropped these requirements31: ‘‘the presence
or absence of myocardial viability in the dysfunctional an-
terior apical segment was not an enrollment criterion.’’ In-
deed, only 38% of STICH participants had any form of
volume measurement, and 13% had no MI.31 It is therefore
unreasonable and impossible to draw any broad conclusions
from the STICH trial based on its patient evaluation
methods, selection criterion, and final assessment on less
than 60% of the enrolled patients.
It seems unrealistic to retrospectively or prospectively
compare the long-term results of coronary revascularization,
mitral repair, ventricular reconstruction, or even heart re-
placement for ICMs when the precise pathophysiology is
not assessed. A large area of ischemic but viable myocar-
dium requires CABG, as opposed to a large irreversibly
scarredwall, which requires ventricular surgery.We strongly
object that revascularization can affect a scarred myocar-
dium, especially when it involves 40% ormore of the perim-
eter of the failing ventricle: this is what LVR is intended to
treat, and it was never proposed as a necessary technique
for a limited anteroapical bulging aneurysm.10,15-17 In the
recent survey from the Cleveland Clinic32 of 4 types of treat-
ment in 1,468 patients with ICMs over 8 years, the authors
did not find any long-term survival difference between
CABG alone and CABG plus SVR (not precisely defined).
But the authors mentioned that ‘‘The decision to pursue
SVR includesMRI studies, viability, and the final inspectionery c April 2011
FIGURE 4. Anteroseptoapical large aneurysm: ‘‘compassionate’’ left ventricular reconstruction indication in an 82-year-old patient with drug-resistant
congestive heart failure in New York Heart Association class IVþ. A1, Preoperative coronary angiogram. A2, Two-chamber view. A3, Gadolinium late en-
hancement on the 4 scarred left ventricular walls (only papillary muscle roots and the lateral wall are not scarred). B1, Endocardial scar. The left internal
thoracic artery (LIMA) was already implanted on the thrombosed left anterior descending coronary artery. B2, After endocardectomy (90 cm2), bleeding
occurring when the left internal thoracic artery is unclamped helps to determine the limit of the resection. B3, Endoventricular reconstruction excluding
half of the anterior wall, two thirds of the interventricular septum, and one third of the posterior wall by using an 8-cm2 patch. C1, Preoperative 4-chamber
view with a sphericity index (SI) of 0.42. C2, Postoperative 4-chamber view 1 month after left ventricular reconstruction with an SI of 0.59. C3, Postop-
erative 4-chamber view at 5 years after left ventricular reconstruction with an SI of 0.48. EDVI, End-diastolic volume index; ESVI, end-systolic volume
index; LVEF, left ventricular ejection fraction; caDVI, contractile area diastolic volume index; LAVI, left atrial volume index.
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not incorporate in our (statistical) model.’’ Again, without
a framework of precise scar and volumetric analysis, the
study’s conclusions become severely weakened and irrele-
vant. In their discussion, the authors recall the point made
earlier by Burkhoff and Weschler33 that ‘‘reducing ventricu-
lar size to improve systolic function makes sense, but (the)
modeling data suggests the equal possibility of worsening
ventricular diastolic function.’’ Thismight have been a possi-
bility in early series of LVRwithout diastolic volume balloon
sizing24,25 but not in our series, in which diastolic function
improved concomitantly with systolic function, as shown
by the decrease in LAVI, which is the best witness to the
decrease in diastolic burden.11The Journal of Thoracic and CaWith regard to MR, it is surprising to see the number of
contradictory publications34-36 of the various techniques
and unsatisfactory long-term results. All these studies are
undermined by the basic fact that ischemic MR is not a val-
vular but a ventricular disease. When MR is due to mitral
annular dilatation, it can be repaired by means of posterior
annuloplasty alone, and when it is related to a scarred lateral
wall, papillary muscle displacement, or both, MR is treated
by means of restoration of papillary muscle location or
valve replacement. The stability of this repair is not linked
to the technique itself but to the concomitant repair of the
cause, mainly ventricular dilatation (ie, the exclusion of
scarred asynergic areas and restoration of concentric sys-
tolic contraction).rdiovascular Surgery c Volume 141, Number 4 911
Months 0 12 24 36 48 60 72 84 96
Subjects at risk 117 111 97 75 58 44 24 13 2
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FIGURE 5. Kaplan–Meier survival curve on 111 ischemic failing ventri-
cle (IFV) survivors 1 year after left ventricular reconstruction (LVR).
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cluded from the STICH trial, the key issue is not to offer
such patients either CABG, CABG plus SVR, or medical
therapies that have already failed but whether they should
undergo ventricular reconstruction or should be considered
for heart replacement. Different factors need to be taken into
consideration. Patients older than 70 years (42% in this se-
ries) are excluded from heart transplantation programs. The
results of an LVassist device in patients with such end-stage
ischemicHF (REMATCHTrial)37 are not in favor of this last
technique comparedwith the results of LVR. Finally, indica-
tions or contraindications for reconstructive surgery (LVR)TABLE 3. Surgical techniques applied in 117 patients
Procedure
Mitral valve surgery 51 patients
Posterior annuloplasty 31 patients
Idþedge-to-edge mitral repair 18 patients
Mitral valve replacement (primary) 1 patient
Mitral valve replacement (after failure
of edge-to-edge repair)
1 patient
Coronary revascularization
Arterial revascularization only 105 patients
Venous graft only 2 patients
No. of distal anastomoses 1.9  0.8 (mean)
Ventricular reconstruction
Endocardectomy 78 patients
Cryotherapy 39 patients
Endoventricular patch 117 patients
Dacron patch 108 patients
Pericardium 9 patients
Septal hinge 2 patients
Cardiopulmonary bypass time (min) 102  35
Aortic crossclamp time (min) 74  23
912 The Journal of Thoracic and Cardiovascular Surgare not based on age or on the degree of severity of HF, pul-
monary hypertension, or MR or the need for intravenous
inotropes or intra-aortic balloon pumping but only on the an-
atomic possibility of rebuilding a contractile LV cavity with
a physiological diastolic capacity.
Figure 6 shows the interest in analyzing the theoretical
caDVI value in the end-stage ischemic ventricle in a hope-
less situation. A 75-year-old patient was stented on the LAD
on day 6 after the onset of acute MI with immediate stent
thrombosis. Three months later, he experienced intractable
HF. He was bedridden in the intensive care unit, undergoing
dobutamine infusion and with pulmonary edema. His pul-
monary artery pressure was 70 mm Hg, and he showed
grade 2þMR. At MRI assessment, EF was 9%, ESVI was
289 mL/m2, EDVI was 320 mL/m2, and the mean scarred
perimeter was 77%. On GLE analysis the caDVI was 70
mL/m2. He was therefore suitable for surgical intervention.
Postoperative assessment showed an EDVI of 76 mL/m2, as
reliably predicted by the caDVI. The patient was controlled
at 1 month and 1 year with progressive improvement and al-
most normal hemodynamic values. This case, as with 4
others on an active heart transplantation waiting list and
alive and well 8, 7, 4, and 3 years, respectively, after
LVR, leads us to believe that with regard to ICMs, indica-
tions for heart transplantation should be revised.
Limitations
The hemodynamic evolution of this series is an observa-
tional study without a control group because patients in
end-stage chronic HF of NYHA class III or IV, despite full
medical or resynchronization therapy, who are already revas-
cularized on the culprit artery bymeans of PCI or surgical in-
tervention, are bedridden, and are receiving intravenous
dobutamine or intra-aortic balloon pumping cannot be
reasonably proposed for other conservative therapies that al-
ready failed. The single alternative is heart transplantation,
and for patients in acute HF with septal rupture or who are in-
tractable ventricular arrhythmia defibrillator resistant and re-
quire rescue surgery, a randomized trial of CABG alone or
medical treatment will never be proposed. It will only be
through the rigorous examination of observational clinical da-
tasets, such as ours, that the effect of LVR will be measured.
CONCLUSIONS
Based on more than 1,300 LVR operations in the last
25 years, we believe that this etiological conservative surgi-
cal technique suppresses the cause and the mechanism of
the IFV by means of endoventricular exclusion of the
scarred wall and restoration of concentric contraction of
the viable myocardium. In the end-stage situation of an
IFV with an asynergic scar of greater than 40% of the LV
perimeter, LVR, with an operative risk of less than 10%
and an improvement at 1 year in more than 80% of survi-
vors, is a therapeutic option superior to other therapeuticsery c April 2011
TABLE 4. LV function in 111 patients surviving 1 year after LVR
EF (%) EDV (mL/m2) ESV (mL/m2) LAV (mL/m2), n ¼ 55
Chronic HF (n ¼ 101)
Preoperative 26  4 (9–34) 130  43 (62–343) 96  45 (45–289) 51  19 (17–94)
1 mo 40  8 (21–64)* 81  27 (46–170)* 50  21 (24–118)* 39  14 (13–72)x
1 y 44  11 (20–69)* 82  25 (33–217)* 47  20 (15–128)y NA
EF (%) EDV (mL/m2) ESV (mL/m2) PAP (mm Hg)
Acute HF (n ¼ 10)
Preoperative 41  6 (32–50) 80  23 (54–122) 48  18 (31–83) 62  18 (38–85)
>1 mo 51  11 (38–68)y 52  18 (28–79)z 27  13 (16–49)z 38  8 (30–49)
>1 y 54  12 (38–72)y 67  25 (32–105)z 34  18 (9–66)z NA
LV, Left ventricular; LVR, left ventricular reconstruction; HF, heart failure; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; LAV, left atrial volume;
PAP, pulmonary artery pressure. *P<.001, effect of time, repeated-measures analysis of variance. yP<.01, effect of time, repeated-measures analysis of variance. zP¼ .01, effect
of time, repeated-measures analysis of variance. xP ¼ .001, paired t test.
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cause of the disease when other therapies try to palliate par-
tially the consequences.
The conclusion of the STICH trial (biased by its selec-
tion and questionable results) on surgical treatment ofFIGURE 6. Giant aneurysm in a hopeless situation (bedridden; brain natriuretic
Contractile area diastolic volume index (caDVI) of 70mL/m2. A1, Preoperative 2
A3, Short-axis view. B1, ‘‘Contractility trail’’ after thromboendocardectomy (11
cavity with exclusion of the anterior wall, four fifths of the septum, half of the p
chamber view at day 15. Excluded left ventricular chamber still visible. C2, Tw
close to the preoperative caDVI (70 mL) with an SI of 0.52. C3, Two-chamber
ESVI, end-systolic volume index; LAVI, left atrial volume index.
The Journal of Thoracic and CaICM is that ‘‘[t]here was no significant difference between
CABG alone and CABG plus surgical ventricular recon-
struction,’’ and is thus unfounded and inappropriate
for a large number of patients with severe ischemic con-
gestive HF.peptide¼ 4,421): heart replacement versus left ventricular reconstruction?
-chamber viewwith a sphericity index (SI) of 0.35.A2, Four-chamber view.
0 cm2). B2, Balloon sizing (90 mL). B3, Rebuilt contractile left ventricular
osterior wall, and one third of the lateral wall by a 10 cm2 patch. C1, Two-
o-chamber view at 1 month. End-diastolic volume index (EDVI; 76 mL) is
view at 1 year with an SI of 0.50. LVEF, Left ventricular ejection fraction;
rdiovascular Surgery c Volume 141, Number 4 913
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Dr Robert H. Jones (Durham, NC). I thank the association for
the invitation to begin this discussion, and I have nothing to dis-
close other than I am the principal investigator of the National
Institutes of Health–funded STICH trial.
Dr Dor contributed to the initial planning of the STICH trial,
insisted that the operation should be called ventricular recon-
struction and not the Dor operation or restoration operation,
and welcomed STICH surgeons into his institution for training.
Today he described 274 patients with ventricular reconstruction
treated concurrently with STICH enrollment and analyzed their
outcomes by who was and was not STICH eligible. Fifty-seven
percent of his patients were STICH eligible. STICH was de-
signed as a broadly inclusive trial. Enrolled patients were those
that responsible investigators and cardiac surgeons at each insti-
tution considered eligible based on their entire clinical picture.
Therefore the combined zone of uncertain benefit about ventric-
ular reconstruction in the minds of all participating cardiologists
and cardiac surgeons largely determined the characteristics of the
1,000 patients randomized. Because STICH was based on clini-
cal judgment for inclusion, specific exclusions were needed toery c April 2011
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Dconstrain the extremes of inclusiveness so that the trial results
could be generalized to a large and well-defined future popula-
tion. For example, the protocol encouraged enrollment of pa-
tients with ongoing Canadian Cardiovascular Society class 3 or
4 angina undergoing intensive medical therapy but did prohibit
enrollment of patients in cardiogenic shock on maximal support.
The shock was not intended to suggest that patients with cardiac
shock would not benefit from ventricular reconstruction surgery;
it was needed for the integrity of the trial. It was considered un-
likely that insufficient numbers of patients with cardiac shock
would be enrolled to make a definitive subgroup conclusion
about their benefit from ventricular surgery. However, should
this high-risk population experience excess deaths in the ventric-
ular reconstruction randomized treatment arm by statistical
chance, these few patients might be contributing enough deaths
to detract statistical power from the primary conclusion in the
broad population of patients more commonly encountered in rou-
tine clinical practice.
However, this STICH protocol exclusion of ischemic shock need
not prohibit use of the neutral results of the STICH trial for manage-
ment decisions for patients with ICMs. For example, in a patient
with cardiac shock, good coronary arteries for revascularization,
and only mild anterior dyskinesia on cardiac catheterization, one
might decide not to obtain a cardiac magnetic resonance (CMR) im-
age to evaluate the need for adding ventricular reconstruction but
would simply consider the ventriculogram and the echocardio-
graphic findings adequate to simply revascularize that patient.
The STICH trial should not be considered as only informing the
question of whether ventricular reconstruction should or should
not be added to CABG for all patients with ICMs. The broader
question the STICH trial informs is how much extra benefit might
accrue from adding ventricular reconstruction to a specific patient
who otherwise might be treated with CABG only.
Dr Dor, you have known the primary outcome of the STICH
trial for more than a year. Most of the patients with ischemic HF
you reported today could have been entered into the STICH trial.
Has this neutral STICH result changed your equipoise for any of
your health care diagnostic or treatment decisions for ‘‘STICH-
like’’ patients, irrespective of whether they were technically
STICH protocol eligible?
Dr Dor. Thank you. First of all, I want to thank you and to con-
firm that your trial, the STICH trial, was a biased trial because
nearly one half of the patients in the IFV condition after infarction
are excluded to not pollute the results of your trial. You confirmed
this fact, and that is very important because I cannot understand
why the scar was not assessed. In your trial there is not one indi-
cation about the size of the scar, its location, or its percentage,
and in the other paper, it was never precise whether the ventricle
was scarred. I agree totally that if a patient is totally ischemic
with grade 4 Canadian Cardiovascular Association ischemia,
you have to revascularize him or her. Nobody discussed the situa-
tion of when a patient has no more ischemia, a totally destroyed
ventricle, and a large scar involving more than 50% of the ventri-
cle: How can CABG alone improve this patient? That is clinically
very ridiculous in a center in which we take care of this patient.
You are out of reality.
The STICH trial is mathematically, for which we have statistics,
irreproachable. It is a fantastic trial. But medically speaking, it isThe Journal of Thoracic and Caunfounded because more than half of the patients were excluded.
You discuss the acute HF. How do you treat a ruptured septum
not excluding the necrosed cavity?
Can you say to a cardiologist: Treat the patient without treating
the cause and its consequence? It is impossible. Therefore the mes-
sage that I want to be received by the community is that when you
have a patient with an IFV, please make a complete and reliable
assessment, and the use, in 2000’sMRI, is mandatory. If the patient
is ischemic, you can revascularize by means of PCI or surgical in-
tervention; it is not a problem and up to you. But if the patient has
a scarred ventricle, rebuild it, but correctly. Because in your trial,
one thing was astonishing, that even if it is only assessed on one
third of 1,000 patients, the decrease in end systolic volume was
something like 16% (from 82 to 68 mL/m2). That is a ridiculous
result for reconstruction. Usually all our patients are below 60
mL/m2, the threshold of prognosis for a patient. I was surprised
by what was published this year at the American College that in
the group of patients with large dilatation, 22% or 23% EF, the in-
crease after surgical intervention was 2 points for revascularization
and 5 points for ventricular reconstruction. What operation was
done? I cannot understand what it is. Is it a new reconstruction
of the ventricle? I showed the results of our whole identical series:
the decrease of ESVI (from preoperative 95 mL/m2 to postopera-
tive 48 mL/m2) reaches 50%.
Therefore you confirmed the fact that you excluded severe pa-
tients to do not pollute your trial, and our presentation confirms
the fact that the STICH trial is not reliable because patients with
a scarred ventricle are not assessed or treated.
Dr Jones. I will respond briefly to permit others to join the dis-
cussion. The STICH trial was not designed to definitively answer
the question of whether ventricular reconstruction should ever be
done in patients with extensive scarring of the left ventricle. Car-
diac surgeons identified patients for whom adding SVR to CABG
would be ethical as long as the LVEF was 0.35 or less and domi-
nant anterior LV dysfunction was present.
We then documented the best available baseline core labora-
tory measurement of global and regional dysfunction and ven-
tricular size reported from the ECHO, SPECT, and CMR core
laboratories without knowledge of the treatment assignment of
the patient. The results to be published soon document a wide
spectrum of ESVI and regional LV function in the 1,000 STICH
patients. Moreover, the change in global LV function from base-
line to 4 months after the operation will be reported based on
the specific operation performed. These will be the first preop-
erative to postoperative LV volume-change data with results re-
ported using data directly quantitated from images by study
readers who could not have known which operation was per-
formed. We also have radionuclide and CMR gadolinium viabil-
ity measurements on a substantial number of these patients that
are likely to provide additional insight about baseline character-
istics of the STICH patients randomized to CABG with or with-
out SVR.
The knowledge the STICH trial contributed about the value of
ventricular reconstruction applies to a broad spectrum of CABG-
eligible patients with ICMs. Clinical outcomes showed no benefit
of ventricular reconstruction throughout the entire range of clin-
ical and cardiac function parameters and were not dependent on
change in volume 4 months after the operation. Becauserdiovascular Surgery c Volume 141, Number 4 915
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strategies were the same for the end points of death, cardiac
hospitalization, and physiological testing, this lack of harm
from ventricular surgery indicates it would be safe to study other
populations for whom a question of benefit for ventricular surgery
added to CABG remains. The STICH trial provides valuable
data that could be used to design future prospective observational
or randomized studies in other ICM patient populations of
interest.916 The Journal of Thoracic and Cardiovascular SurgDr Dor. I will answer very quickly. I thank you to mention the
neutral results of the STICH trial. Your conclusion must add as
a conclusion that all the cases that were not treated by the STICH
study team will be interesting for cardiologists. Second, regarding
the volumes you mentioned, they are assessed by means of
echocardiographic analysis, and again, in 2000’s magnetic reso-
nance is more reliable to assess the volume of the heart before
and after repair.
I thank you for your comments and I thank the association.ery c April 2011
FIGURE E1. Linear relationship between infarct size/degree of advanced heart failure (AHF) II in patients with percutaneous coronary intervention (PCI)
for coronary recanalization at the acute phase of myocardial infarction (AMI). A, Scar extension (percentage of left ventricular [LV] perimeter) in 229
patients. B, Degrees of advanced HF according to percentage of scar extension.
FIGURE E2. Mechanism of left ventricular dilatation in a 61-year-old patient with anterior myocardial infarction (MI) on August 5, 2005 (percutaneous
coronary intervention þ stent followed by congestive heart failure and intra-aortic balloon pumping). A, Immediately after myocardial infarction I,
contractile myocardium surrounding the fresh necrosis (MVO) has a centripetal movement during systole (mitral leaflets closed)¼ systolic eccentric motion
(arrows; see Video 1). B, The definitive scar extension (gadolinium late enhancement [GLE]) of greater than 50% leads to progressive dilatation: in 4
months, the end-systolic volume index (ESVI) exceed the threshold of 60 mL/m2 (see Videos 2 and 3).
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FIGURE E3. Reasons why left ventricular reconstruction (LVR) is efficient (same patient as Figure E2). A1, Scar extension. Contractile area diastolic vol-
ume index (caDVI), 44 mL/m2; sphericity index (SI), 0.35. A2, Eccentric systolic motion (arrows; see Video 4). B1, Endocardial scar. B2, Contractile myo-
cardium after endocardectomy (92 cm2). B3, Circular reorganization of contractile myocardium with a 6-cm2 patch. C1, Postoperative gadolinium late
enhancement (GLE; scar<20%). C2, Left ventricular cavity with restored systolic concentric contraction (arrows). End-systolic volume index (ESVI),
51 mL (close to theoretical preoperative caDVI); SI, 0.50 (Video 5). LVEF, Left ventricular ejection fraction; EDVI, end-diastolic volume index.
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FIGURE E4. Posterior aneurysm (56-year-old patient with congestive heart failure, class IV, plus cardiac arrest with ventricular tachycardia). A, Preop-
erative magnetic resonance imaging assessment. A1, Left ventricular outflow tract view (see video 6). A2, Short-axis view showing the eccentric systolic
motion (arrows; see Video 7). A3, Gadolinium late enhancement on the aneurismal wall on the left ventricular outflow tract and 3 bis on short-axis view.
PVS, Programmed ventricular stimulation. B, Perioperative view. B1, Posterior wall on an empty heart. B2, The ‘‘contractility trail’’ at the limit between the
akinetic and kinetic walls. B3, The triangular patch reapproximates the lateral and septal walls without mitral annular distortion. C, Postoperative magnetic
resonance imaging assessment.C1, Left ventricular outflow tract and 1 bis short-axis views at 1 month (see Videos 8 and 9).C2, Left ventricular outflow tract
and 2 bis short-axis views at 1 year, showing clearly restoration of concentric systolic contraction (arrows; see Videos 10 and 11). LVEF, Left ventricular
ejection fraction; EDVI, end-diastolic volume index; ESVI, end-systolic volume index.
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FIGUREE5. Anteroseptal rupture exclusion in a 76-year-old patient 1 month after left anterior descending coronary artery recanalization for myocardium
infarction. A1, Two-chamber view of the necrotic aneurysm and eccentric systolic motion of the border zone. Contractile area diastolic volume index
(caDVI), 48 mL/m2; sphericity index (SI), 0.38 (see Video 12). A2, Short-axis view. The septal rupture is a dissection of the septum (see Video 13). A3,
Septal rupture approached by means of anterior ventriculotomy. B4, Exclusion of ruptured septum from the rebuilt left ventricular cavity with patch inserted
on normalmyocardium.B5, Postoperative 2-chamber view at 1month. The excluded necrotic area is still visible (see Video 14).B6, Normalization of the left
ventricular aspect at 1 year. End-diastolic volume index (EDVI), 40 mL (close to the preoperative caDVI at 48 mL and restoration of concentric systolic
contraction); SI, 0.23 (see Video 15). EF, Ejection fraction; ESVI, end-systolic volume index; VSD, ventricular septal defect.
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